N/A N=190 Attain Model 4196 Left Ventricular (LV) Lead
Heart Failure
Primary: Safety (Subjects Without a Model 4196 Lead Related Complication) — 168 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=197 Model 4396 Left Ventricular (LV) Lead Study
Heart Failure
Primary: Safety (Subjects Without a Model 4396 Lead Related Complication) — 155 participants
N/A N=349 Impact of Heart Failure Center Program on Cardiac Outcomes in Patients With Heart Failure
Death · Congestive Heart Failure
Primary: All-cause Death, Heart Failure-related Re-hospitalizations, and a Composite Outcome of Both Death and Heart Failure-related Re-hospitalizations — 36; 15; 41; 18…
Phase 3 N=133 PUFAs and Left Ventricular Function in Heart Failure
Dilated Cardiomyopathy · Heart Failure
Primary: Change in Left Ventricular (LV) Systolic Function Expressed as Left Ventricular Ejection Fraction (LVEF) Between Baseline and 12-month Follow-up — 36; 37; 39; 35…
N/A N=335 Heart Failure Study: The Atlanta Cardiomyopathy Consortium
Heart Failure
Primary: Death, Heart Transplant, Left Ventricular Assist Device Implantation — 35 participants
N/A N=211 Identifying and Facilitating Ventricular Recovery on Mechanical Support
Heart Failure
Primary: Number of Subjects With Left Ventricular Recovery and LVAD Explant — 8 Participants
N/A N=90 Model 4296 Left Ventricular (LV) Lead Study
Heart Failure
Primary: Number of Participants With Left Ventricular (LV)Lead Related Complications — 1 participants
Phase 2 N=130 B-lines Lung Ultrasound Guided ED Management of Acute Heart Failure Pilot Trial
Heart Failure · Heart Failure Acute · Acute Cardiac Pulmonary Edema
Primary: Number of Participants With B-lines ≤ 15 at the Conclusion of ED AHF Management — 7; 10 Participants
Phase 4 N=365 EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)
Heart Failure
Primary: Change in NT-proBNP — 0.14; 0.19 unitless — p=0.45
N/A N=50 The Right Ventricular Pulmonary Circulation Continuum in Mitral Valve Disease Study
Mitral Regurgitation · Pulmonary Hypertension
Primary: Impaired Post-operative Functional Capacity — 35 Participants
N/A N=918 Biventricular Versus Right Ventricular Pacing in Heart Failure Patients With Atrioventricular Block (BLOCK HF)
Atrioventricular Block · Heart Diseases
Primary: Mortality, Heart Failure-related Urgent Care Visits, or Significant Increase in Left Ventricular End Systolic Volume Index (LVESVI) — 160; 191; 93; 136 participants…
N/A N=15 Right Ventricular Function and Exercise Capacity in Patients With Continuous-flow Left Ventricular Assist Devices
Heart Failure
Primary: Peak Oxygen Uptake — 15 ml/kg/min
Phase 2 N=10 Interleukin-1 Receptor Antagonist for the Treatment of Heart Failure in Patients With Left Ventricular Assist Devices
Heart Failure
Primary: Biologic Efficacy: Inflammation Marker - C-Reactive Protein — 2.5; 0.6; 0.6 mg/dL
Phase 4 N=42 Levosimendan Efficacy Assessment by Cardiopulmonary Exercise Test (CPET)
Heart Failure
Primary: Change in Peak VO2 (Oxygen Consumption ) — 1.21; 0.48 ml/kg/min
Phase 2 N=301 LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction
Chronic Heart Failure
Primary: Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) — 0.83; 1.08 ratio: endpoint/baseline (pg/mL)
N/A N=101 Investigation to Optimize Hemodynamic Management of Left Ventricular Assist Devices Using the CardioMEMS™
Heart Failure
Primary: Six Minute Hall Walk (6MHW) Distance — -44.9; 69.7 meters — p=0.001
Phase 4 N=300 Clinical Study of Lipoic Acid on Ischemic Heart Failure
Ischemic Heart Failure
Primary: Number of Participants That Had First Occurrence of the Composite Endpoint — 32; 40 Participants
N/A N=111 Left Atrial Distensibility to Predict Left Ventricular Filling Pressure and Prognosis in Patients With Severe Mitral Regurgitation
Mitral Valve Insufficiency · Atrial Fibrillation · Heart Failure
Primary: Left Ventricular Filling Pressure More Than 15 mmHg Measured by Left Ventricular Catheterization — 25.5 mmHg
Phase 2 N=58 Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction
Congestive Heart Failure
Primary: Change in Natriuresis (Urinary Sodium Excretion) in Control Subjects at 60 Minutes After Volume Expansion Compared to Baseline in Response to Placebo Treatment — 87.19…
Phase 2 N=10 Myocardial Hemodynamic Effects of Levosimendan
Heart Failure
Primary: Change in Left Ventricular End-diastolic Pressure (LVEDP) Using Pressure-volume Catheter. — 5.67 mmHg
Phase 4 N=10 Effects of Viagra on Heart Function in Patients With Heart Failure
Heart Failure · Left Ventricular Dysfunction
Primary: Reduction of the Left Ventricular Filling Pressure in Association With Administration of Sildenafil — 16.7; 16.4 E/e' ratio
N/A N=15 An Assessment of Dual Site Left Ventricular Endocardial Pacing
Atrial Fibrillation · Ventricular Tachycardia · Heart Failure
Primary: Acute Haemodynamic Response to Dual Left Ventricular Pacing — 3.7 % difference — p=<0.05
N/A N=513 The Darlington Retrospective Outpatient Study
Heart Failure
Primary: All Cause Mortality — 163; 118 participants
Phase 4 N=57 Loop Diuretics Administration and Acute Heart Failure
Acute Heart Failure
Primary: Evaluation of Mean Urine Output Volume During the Infusion Period — 2505; 2140 mL — p=0.04
N/A N=610 REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE)
Heart Failure
Primary: Percentage of Patients Worsened for Clinical Composite Response — 21.5; 16 Percentage of participants worsened — p=0.10
Phase 2 N=71 Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction
Heart Failure
Primary: Change in Left Ventricular End Systolic Volume (ml) — -4.4; -1.2; -3.8 mL
Phase 2 N=25 Stem Cell Therapy in Patients With Severe Heart Failure & Undergoing Left Ventricular Assist Device Placement
Heart Failure
Primary: Safety of Cell Delivery — 1; 0 adverse events
Phase 3 N=882 Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass
Coronary Artery Bypass Grafting · Mitral Valve Surgery · Low Cardiac Output Syndrome
Primary: Number of Dual Efficacy Endpoint Events — 56; 48 events
Phase 3 N=216 Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)
Heart Failure
Primary: Exercise Capacity, as Determined by Peak Oxygen Uptake — -0.07; -0.12 ml/min/kg
Phase 1 N=40 Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure
Heart Failure
Primary: Safety of Single Ascending Doses of GGF2 Via an Assessment of the Toxicology Profile as Measured by Treatment Emergent Adverse Events (TEAEs) — 6; 4; 4; 2 participants